E. Michailidis

A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist

The paper identifies PLSCR1 as a host factor restricting SARS-CoV-2 entry, which recent variants have evolved to bypass, through a CRISPR screen and integration of genetic studies.

Human hepatocyte PNPLA3 148M exacerbates rapid non-alcoholic steatohepatitis development in chimeric mice

This study shows that the PNPLA3 148M variant in human hepatocytes worsens non-alcoholic steatohepatitis in chimeric mice on a hypercaloric diet.

Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks

The paper identifies host factors required for SARS-CoV-2 and three seasonal coronaviruses using CRISPR screens, revealing shared and virus-specific dependencies.

Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors

The paper identifies host factors critical for SARS-CoV-2 and related coronaviruses using CRISPR screens, revealing both shared and unique factors across different viruses and temperatures.

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro

This study shows that secretory IgA, particularly dimers, are more potent than IgG in neutralizing SARS-CoV-2 in vitro, suggesting their importance for mucosal protection and vaccine design.

Development of Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine (EFdA) by Wild-Type and Nucleoside Reverse Transcriptase Inhibitor Resistant Human Immunodeficiency Virus Type 1

This study identifies mutations conferring resistance to EFdA in HIV-1, showing M184V as the primary determinant and A114S enhancing resistance.

LY6E impairs coronavirus fusion and confers immune control of viral disease

This study identifies LY6E as an interferon-induced gene that restricts coronavirus entry and pathogenesis by inhibiting spike protein-mediated fusion and protecting immune cells.

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

The paper shows SARS-CoV-2 variants resistant to neutralizing antibodies can be selected and are present in circulating populations, suggesting the need for combination antibody therapies.

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

The paper describes assays using pseudotyped and chimeric viruses to measure SARS-CoV-2 neutralizing antibody activity, showing correlation with authentic assays.

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

The paper analyzes antibody responses in convalescent individuals, finding low neutralizing titers but rare potent RBD-specific antibodies with broad antiviral potential.

Public broadly neutralizing antibodies against hepatitis B virus in individuals with elite serologic activity

The paper identifies broadly neutralizing antibodies against HBV in elite neutralizers and shows that combinations of bNAbs targeting different epitopes are more effective than single bNAbs.

An RNA-based system to study hepatitis B virus replication and select drug-resistance mutations

This paper describes an RNA-based system to study HBV replication and predict drug resistance mutations.

A short HBV RNA region induces RNR-R2 expression in non-cycling cells and in primary human hepatocytes

The paper identifies a 125-base RNA region in HBV transcripts that induces RNR-R2 expression in non-cycling cells and primary human hepatocytes without requiring HBx protein.